SCHEMBL20134860

SCHEMBL20134860

Cc1cccnc1N1CCN(C(=O)c2ccc([C@@]3(C(C)C)NC(=O)NC3=O)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 3/20 0.43
TRPV1 Q8NER1 4/20 0.42
HSD11B1 P28845 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ADAMTS5 Q9UNA0 5/20 0.40
ADAM17 P78536 1/20 0.40
PARP1 P09874 1/20 0.40
AVPR1A P37288 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MMP1 P03956 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688546 1.00 SLC6A7 (0.43) SLC6A7TRPV1HSD11B1KDM4EADAMTS5
SCHEMBL20134864 1.00 SLC6A7 (0.43) SLC6A7TRPV1HSD11B1KDM4EADAMTS5
SCHEMBL20134989 0.86 ALDH1A1 (0.40) SLC6A7KDM4EADAMTS5ADAM17MEN1
SCHEMBL20134972 0.86 ALDH1A1 (0.40) SLC6A7KDM4EADAMTS5ADAM17MEN1
SCHEMBL20135672 0.85 SMN1; SMN2 (0.47) ADAMTS5ADAM17L3MBTL1MEN1KMT2A
SCHEMBL20135673 0.85 SMN1; SMN2 (0.47) ADAMTS5ADAM17L3MBTL1MEN1KMT2A
SCHEMBL20134817 0.83 ALDH1A1 (0.37) KDM4EADAMTS5ADAM17MEN1KMT2A
SCHEMBL29688621 0.83 ALDH1A1 (0.37) KDM4EADAMTS5ADAM17MEN1KMT2A
SCHEMBL20135547 0.83 KDM4E (0.37) SLC6A7KDM4EADAMTS5ADAM17MEN1
SCHEMBL29689068 0.83 KDM4E (0.37) SLC6A7KDM4EADAMTS5ADAM17MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 SLC6A7 3698/4885TRPV1 1491/4885HSD11B1 1694/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 SLC6A7 3473/4885TRPV1 1527/4885HSD11B1 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.